Clinical Trials Logo

Filter by:
NCT ID: NCT06451172 Recruiting - Eye Diseases Clinical Trials

Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis

ASOTARI
Start date: October 11, 2023
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of GP-asPNA for in vivo treatment of severe antibiotic resistant bacterial keratitis.

NCT ID: NCT06450340 Active, not recruiting - Clinical trials for Visual Impairment and Blindness (Excl Colour Blindness)

A Trial of Tai Chi Intervention for Youngsters With Visual Impairments

Start date: April 22, 2024
Phase: N/A
Study type: Interventional

Investigators conducted a single-blind, randomized trial of Taijiquan exercise as compared with a control intervention consisting of wellness education and jogging for youngsters with visual impairments. Sessions lasted 60 minutes each and took place three times a week for 12 weeks for each of the study groups. The primary end point was a change in the Brockport Physical Fitness Test (BPFT) at the end of 12 weeks. Secondary end points included summary scores of the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) and Pittsburgh Sleep Quality Index (PSQI)at the end of 12 weeks.

NCT ID: NCT06450145 Recruiting - Tumour Clinical Trials

Evaluate the Efficacy and Safety of Interferon-α Combined With ATO in the Treatment of Arsenic-resistant APL

APL
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

This study was a single-arm, open study. After the screening period, arsenic-resistant APL patients were treated with interferon α-2b, arsenic and venetoclax. The efficacy (ORR) and safety were evaluated.

NCT ID: NCT06449976 Recruiting - Clinical trials for Longitudinal Chromatic Aberration

Application and Clinical Evaluation of Longitudinal Chromatic Aberration Technique in Ophthalmology

Start date: June 2024
Phase: N/A
Study type: Interventional

Our study aims to delve into the effects of shifting the focal point of blue light from video or text displayed on a terminal screen forward on the axial length of the eye, ocular blood flow, visual fatigue, and visual function, that is, its relationship with Video Display Terminal (VDT) syndrome and myopia. By examining the decoding ability of the adult subjects' retina to the clarity of the signal, we will attempt to develop a novel, non-invasive strategy to curb the elongation of the eyeball associated with myopia. Concurrently, we will also focus on the pathophysiological mechanisms underlying VDT syndrome and explore its potential link to the progression of myopia, providing new scientific evidence for the prevention and treatment of this ocular condition. This research is expected to provide robust support for addressing the global issue of myopia and the health challenges posed by VDT syndrome. Ultimately, by integrating global eye health issues with the challenges brought about by VDT syndrome, we will propose intervention and prevention strategies, offering new insights for the advancement of ophthalmology and public health sectors, thereby promoting visual acuity and ocular health for the population.

NCT ID: NCT06449937 Recruiting - Clinical trials for Metastatic Colorectal Carcinoma

Local Liver Treatment for Multi-organ Colorectal Cancer Metastases

Start date: July 2024
Phase: N/A
Study type: Interventional

The purpose of this study was to investigate the effect of only local radical treatment of liver metastases combined with systematic treatment in the treatment of patients with multiple organ metastases of colorectal cancer, whether it can benefit the prognosis and explore the risk factors related to the prognosis.

NCT ID: NCT06449911 Active, not recruiting - Clinical trials for Middle and Lower Face and Submental Region Skin Laxity

The Efficacy of Microfocused Ultrasound Technique in the Treatment of Facial Skin Laxity

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

This is a prospective study of 20 Chinese patients with lower facial laxity treated by High Intense focused ultrasound (HIFU). Response will be assessed via paired comparison of pretreatment and posttreatment photographs by two independent dermatologists, grading on a 5-point Subject Global Aesthetic Improvement Scale (SGAIS) for skin laxity. Quantitative analysis of submental lifting will also be performed. Patient's level of "sagging" and "volume loss", satisfaction and tolerance will be documented.

NCT ID: NCT06449885 Recruiting - Clinical trials for Marginal Zone Lymphoma

A Cohort Study in Newly Diagnosed MZL

Start date: May 30, 2024
Phase:
Study type: Observational

Describe the clinical features, diagnosis and treatment status, disease course and primary outcomes of different subtypes of marginal zone B-cell lymphoma (MZL), observe the therapeutic efficacy and safety of different treatment modalities.

NCT ID: NCT06449859 Active, not recruiting - Asthma Clinical Trials

A Clinical Trial of TQC2938 Injection in Healthy Adult Subjects

Start date: June 13, 2023
Phase: Phase 1
Study type: Interventional

The study is designed in two phases: single-dose administration and multiple-dose administration. A randomized, double-blind, placebo-controlled trial design was used to evaluate the safety, tolerability, pharmacokinetic characteristics and immunogenicity of TQC2938 injection in healthy adults.

NCT ID: NCT06449846 Not yet recruiting - Surgery Clinical Trials

Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma

Start date: June 1, 2024
Phase:
Study type: Observational [Patient Registry]

The aim of this study was to compare the accuracy of ctDNA-MRD longitudinal surveillance model and internationally accepted pathological MVI results in predicting recurrence after radical hepatectomy. At the same time, to explore the relationship among the two methods of predicting recurrence of hepatocellular carcinoma, postoperative adjuvant therapy and postoperative recurrence, this study further confirmed the effectiveness of ctDNA-MRD longitudinal monitoring model in monitoring postoperative recurrence of hepatocellular carcinoma and guiding treatment.

NCT ID: NCT06449833 Recruiting - Clinical trials for Type2 Diabetes Mellitus

Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD

HHTN
Start date: June 2024
Phase: Phase 4
Study type: Interventional

This study focuses on the effects of Henagliflozein on hepatic fat content in patients with type 2 diabetes mellitus (DM) and nonalcoholic fatty liver disease (NAFLD). Sponsored by Zhujiang Hospital of Southern Medical University, this study is a multi-center, randomized, controlled clinical trial, aiming at exploring the difference in the reduction of liver fat content in the subjects compared with the control group after 24 weeks of treatment. Subjects from different medical centers diagnosed with T2DM and NAFLD will be randomly assigned to the treatment or control group in a 1:1 ratio, and subsequently initiate the intervention period of 24 weeks. In this trial, patients will be treated with 10 mg of Henagliflozein + metformin and 5 mg of Linagliptin + metformin as control, and the dose of metformin will be customized at 500-1500mg according to their individual blood glucose level. The check-points are set at the 8th, 16th and 24th week of the follow-up after the treatment, and nutritionists are available to provide dietary and exercise guidance.